1) Schramek D, Leibbrandt A, Sigl V et al:Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98-102, 2010
2) Gonzalez-Suarez E, Jacob AP, Jones J et al:RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107, 2010
3) Schramek D, Sigl V, Penninger JM:RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 22:188-194, 2011
4) Jones DH, Nakashima T, Sanchez OH et al:Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696, 2006
5) Tan W, Zhang W, Strasner A et al:Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548-553, 2011
6) Body JJ, Facon T, Coleman RE et al:A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228, 2006
7) Yonemori K, Fujiwara Y, Minami H et al:Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 99:1237-1242, 2008
8) Stopeck AT, Lipton A, Body JJ et al:Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
9) Van Poznak CH, Temin S, Yee GC et al:American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227, 2011
10) Fizazi K, Carducci M, Smith M et al:Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study. Lancet 377:813-822, 2011
11) Vij R, Horvath N, Spencer A et al:An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol 84:650-656, 2009
12) Yasuda Y, Kaleta J, Bromme D:The role of cathepsins in osteoporosis and arthritis:rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973-993, 2005
13) Jensen AB, Wynne C, Ramirez G et al:The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases:results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 10:452-458, 2010
14) Soriano P, Montgomery C, Geske R et al:Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702, 1991
15) Marzia M, Sims NA, Voit S et al:Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311-320, 2000
16) Saad F, Lipton A:SRC kinase inhibition:targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36:177-184, 2010
17) Yu EY, Wilding G, Posadas E et al:Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15:7421-7428, 2009
18) Lara PN Jr, Longmate J, Evans CP et al:A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer:a California Cancer Consortium study. Anticancer Drugs 20:179-184, 2009
19) Takahashi S, Miyazaki M, Okamoto I et al:Phase I study of dasatinib(BMS-354825)in Japanese patients with solid tumors. Cancer Sci 102:2058-2064, 2011
20) Felding-Habermann B:Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20:203-213, 2003
21) Nakamura I, Duong le T, Rodan SB et al:Involvement of αvβ3 integrins in osteoclast function. J Bone Miner Metab 25:337-344, 2007
22) Rosenthal MA, Davidson P, Rolland F et al:Evaluation of the safety, pharmacokinetics and treatment effects of an αvβ3 integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol 6:42-48, 2010
23) Ozaki S, Tanaka O, Fujii S et al:Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 86:180-185, 2007
24) Mukherjee S, Raje N, Schoonmaker JA et al:Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118:491-504, 2008
25) Qiang YW, Hu B, Chen Y et al:Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113:4319-4330, 2009
26) Padmanabhan S:A phase I/II study of BHQ880, a novel osteoblast activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma(MM)patients treated with zoledronic acid(Zol)and anti-myeloma therapy(MM Tx). ASH #750, 2009(abstr)
27) Edwards CM, Edwards JR, Lwin ST et al:Increasing Wnt signaling in the bone marrow micro-environment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111:2833-2842, 2008
29) Moester MJ, Papapoulos SE, Lowik CW et al:Sclerostin:current knowledge and future perspectives. Calcif Tissue Int 87:99-107, 2010
30) Terpos E, Christoulas D, Katodritou E et al:Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma:reduction post-bortezomib monotherapy. Int J Cancer, 2011(in printing)
31) Padhi D, Jang G, Stouch B et al:Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26, 2011
32) Vallet S, Mukherjee S, Vaghela N et al:Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 107:5124-5129, 2010
33) Terpos E:Elevated levels of circulating activin-A correlate with features of advanced disease, extensive bone involvement and inferior survival in patients with multiple myeloma. ASH #2967, 2010(abstr)
34) Bagnato A, Loizidou M, Pflug BR et al:Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 163:220-233, 2011
35) Guise TA, Yin JJ, Mohammad KS:Role of endothelin-1 in osteoblastic bone metastases. Cancer 97:779-784, 2003
36) Nelson JB, Nabulsi AA, Vogelzang NJ et al:Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169:1143-1149, 2003
37) James ND, Caty A, Payne H et al:Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan(ZD4054)in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain:a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 106:966-973, 2010